TNKase tenecteplase: Marketed in U.S.; under review in Europe

Patients given TNKase plus Clexane had an event rate of 13.75% compared to 17.04% for TNKase and UFH (p=0.0081). The TNKase plus UFH and ReoPro

Read the full 257 word article

How to gain access

Continue reading with a
two-week free trial.